NAGE Key Statistics, Chart & Performance
The current stock price of NAGE is 5.1 USD. In the past month the price decreased by -21.78%.
NAGE Technical Analysis
NAGE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NAGE. NAGE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
NAGE Financial Highlights
Over the last trailing twelve months NAGE reported a non-GAAP Earnings per Share(EPS) of 0.24. The EPS increased by 2300% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.38% | ||
| ROA | 20.82% | ||
| ROE | 28.91% | ||
| Debt/Equity | 0 |
NAGE Forecast & Estimates
11 analysts have analysed NAGE and the average price target is 16.12 USD. This implies a price increase of 216% is expected in the next year compared to the current price of 5.1.
For the next year, analysts expect an EPS growth of 85.64% and a revenue growth 30.96% for NAGE
NAGE Ownership
NAGE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 22.03 | 203.947B | ||
| DHR | DANAHER CORP | 25.51 | 153.002B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 150.09 | 50.357B | ||
| A | AGILENT TECHNOLOGIES INC | 21.06 | 36.736B | ||
| IQV | IQVIA HOLDINGS INC | 14.73 | 31.929B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.87 | 28.062B | ||
| WAT | WATERS CORP | 22.68 | 22.698B | ||
| ILMN | ILLUMINA INC | 22.65 | 18.293B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.71 | 17.909B | ||
| MEDP | MEDPACE HOLDINGS INC | 31.55 | 15.269B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NAGE
Company Profile
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
Company Info
NIAGEN BIOSCIENCE INC
10900 Wilshire Blvd Suite 600
Los Angeles CALIFORNIA US
Employees: 104
Phone: 13103886706
NIAGEN BIOSCIENCE INC / NAGE FAQ
What does NAGE do?
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
Can you provide the latest stock price for NIAGEN BIOSCIENCE INC?
The current stock price of NAGE is 5.1 USD. The price decreased by -1.92% in the last trading session.
What is the dividend status of NIAGEN BIOSCIENCE INC?
NAGE does not pay a dividend.
What is the ChartMill rating of NIAGEN BIOSCIENCE INC stock?
NAGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for NAGE stock?
11 analysts have analysed NAGE and the average price target is 16.12 USD. This implies a price increase of 216% is expected in the next year compared to the current price of 5.1.
What is the GICS sector and industry of NAGE stock?
NIAGEN BIOSCIENCE INC (NAGE) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is NIAGEN BIOSCIENCE INC worth?
NIAGEN BIOSCIENCE INC (NAGE) has a market capitalization of 407.03M USD. This makes NAGE a Small Cap stock.